Control Bionics Limited (ASX:CBL)

Control Bionics Statistics

Total Valuation

Control Bionics has a market cap or net worth of AUD 13.79 million. The enterprise value is 13.55 million.

Market Cap	13.79M
Enterprise Value	13.55M

Important Dates

The next estimated earnings date is Tuesday, November 25, 2025.

Earnings Date	Nov 25, 2025
Ex-Dividend Date	n/a

Share Statistics

Control Bionics has 336.34 million shares outstanding. The number of shares has increased by 65.68% in one year.

Current Share Class	336.34M
Shares Outstanding	336.34M
Shares Change (YoY)	+65.68%
Shares Change (QoQ)	+27.84%
Owned by Insiders (%)	18.50%
Owned by Institutions (%)	5.44%
Float	124.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.24
PB Ratio	2.50
P/TBV Ratio	8.44
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.22
EV / Sales	2.21
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.96

Financial Position

The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.08.

Current Ratio	1.24
Quick Ratio	1.00
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	-0.10
Interest Coverage	-54.67

Financial Efficiency

Return on equity (ROE) is -103.74% and return on invested capital (ROIC) is -56.53%.

Return on Equity (ROE)	-103.74%
Return on Assets (ROA)	-43.14%
Return on Invested Capital (ROIC)	-56.53%
Return on Capital Employed (ROCE)	-104.89%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.71
Inventory Turnover	4.99

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.79% in the last 52 weeks. The beta is 0.01, so Control Bionics's price volatility has been lower than the market average.

Beta (5Y)	0.01
52-Week Price Change	-32.79%
50-Day Moving Average	0.04
200-Day Moving Average	0.04
Relative Strength Index (RSI)	62.79
Average Volume (20 Days)	448,207

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Control Bionics had revenue of AUD 6.14 million and -6.11 million in losses. Loss per share was -0.02.

Revenue	6.14M
Gross Profit	4.11M
Operating Income	-5.96M
Pretax Income	-6.11M
Net Income	-6.11M
EBITDA	-5.14M
EBIT	-5.96M
Loss Per Share	-0.02

Balance Sheet

The company has 672,657 in cash and 435,398 in debt, giving a net cash position of 237,259 or 0.00 per share.

Cash & Cash Equivalents	672,657
Total Debt	435,398
Net Cash	237,259
Net Cash Per Share	0.00
Equity (Book Value)	5.51M
Book Value Per Share	0.02
Working Capital	619,381

Cash Flow

In the last 12 months, operating cash flow was -4.27 million and capital expenditures -302,327, giving a free cash flow of -4.57 million.

Operating Cash Flow	-4.27M
Capital Expenditures	-302,327
Free Cash Flow	-4.57M
FCF Per Share	-0.01

Margins

Gross margin is 66.94%, with operating and profit margins of -96.95% and -99.41%.

Gross Margin	66.94%
Operating Margin	-96.95%
Pretax Margin	-99.41%
Profit Margin	-99.41%
EBITDA Margin	-83.64%
EBIT Margin	-96.95%
FCF Margin	n/a

Dividends & Yields

Control Bionics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-65.68%
Shareholder Yield	-65.68%
Earnings Yield	-44.30%
FCF Yield	-33.15%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Control Bionics has an Altman Z-Score of -4.56 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.56
Piotroski F-Score	2